Citi lowered the firm’s price target on Biohaven (BHVN) to $14 from $28 and keeps a Buy rating on the shares. The firm cites the complete response letter in spinocerebellar ataxia for the target cut. Citi remains cautious into Biohaven’s upcoming Phase 3 depression data but says the recent equity raise alleviates a near-term financing overhang.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN: